Inky receives series A funding to enhance analytics capabilities of the software and expand sales and marketing.
Inky Technology Corporation, the leading email security company based in Rockville, Maryland, announces today that ClearSky Security led the Series A round to invest $5.6 million to enhance analytics capabilities of the software and expand sales and marketing. Gula Tech Adventures also participated in the round, and Blackstone (NYSE:BX) has joined as a strategic investor. ClearSky Security Managing Director Peter Kuper has joined CEO/founder Dave Baggett, co-founder Simon Smith, and The Kroger Co. (NYSE: KR) CIO Chris Hjelm on the company’s board of directors.
The Iowa AgriTech Accelerator recently announced the five AgTech startups selected for the program’s class of 2018.
Based in Des Moines, the accelerator is a mentor-led program that focuses on ag-based technology innovations. This year’s class is the second to go through the 100-day program.
From cofounding Sirius Satellite Radio to launching a biotech company to find a cure for her daughter’s illness, Martine Rothblatt has had so much career success that any one of her accomplishments would be a crowning achievement for another entrepreneur. “I always try to convert a moonshot into an earthshot,” Rothblatt told hundreds at the Forbes Women’s Summit on Tuesday.
When her husband was dying of a drug-resistant infection, Steffanie Strathdee had a last-ditch idea. They could try treating him with a virus that would kill the bacteria colonizing his insides. The method, called phage therapy, was popular in former Soviet republics, but had mostly been abandoned in the U.S. Researchers had to hunt for the right virus in Texas pigsties and sewage treatment plants.
What started with a wife’s stubborn refusal to give up on her husband who lay dying of a superbug infection has become a whole new research initiative at UC San Diego.
Silence Therapeutics has appointed Dave Lemus to its Board as non-executive director and Richard Jenkins as head of clinical development. Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. He is currently executive vice chair, chief operating officer and CFO of Proteros biostructures. He also currently serves as a non-executive board member of BioHealth Innovation, Sorrento Therapeutics, and the MIT Club of Washington DC.
Marriott International, the world’s largest hotel chain, on Thursday broke ground on the $600 million project to build a headquarters in downtown Bethesda.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., Ltd. for the manufacturing of entecavir and cilostazol. Yiling Wanzhou International Pharmaceutical Co., Ltd. is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd. The contracted manufacturing facilities have been inspected by both the U.S. Food and Drug Administration (FDA) and China FDA (CFDA) and operate to strict International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Manufacturing Practice (GMP) standards, which will enable CASI to eventually sell both entecavir and cilostazol in the U.S., China and worldwide markets. Entecavir and cilostazol are part of the 29 abbreviated new drug applications (ANDAs) that CASI acquired from Sandoz in January 2018.
An exciting job opportunity is available to work in the Technology Transfer Center (TTC), National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Service (DHHS).
If you have experience providing leadership and direction on all matters related to the development & management of technology transfer and patenting and licensing then consider becoming a Supervisory Technology Transfer & Patent Specialist at the NCI!
There have been many a product over the years aimed at getting help to seniors who suffered a fall. But when Erich Meissner’s grandmother had a fall of her own, her device didn’t work for her — because she wasn’t wearing it, a problem the University of Maryland alum found to be widespread.
Joel Grimwood needed a new heart, but a chronic bacterial infection lurking within his implanted ventricle assist device made getting one impossible. Five transplant centers declined his case due to his persistent infection. Then Grimwood came to UC San Diego Health, where doctors treated the infection with an experimental bacteriophage therapy – viruses that eat bacteria. The infection cleared and Grimwood got his new heart.
United Therapeutics CEO Martine Rothblatt may not sound like a familiar name to an average person, but in the healthcare industry, she is a living legend. Rothblatt was the second-highest paid female CEO in the U.S. in 2017—and the 19th highest paid overall. (She was the highest-paid female CEO in the U.S. in 2013.)
When you hear the term “government research” do the words “entrepreneur”, “start-up”, “commercially relevant” or “industry partner” come to mind?
For many, they would not. However, if you attended the Second Annual Technology Showcase last week hosted by NCI and the Frederick National Laboratory for Cancer Research (FNLCR) those are the words that came up in each and every presentation. This event wasn’t your average government research poster session showcasing incredibly interesting, yet commercially irrelevant studies. This event was all about the commercially relevant technologies being developed at the NCI and FNLCR that have the potential to take to patients, and the success stories of those that already have.
TEDCO plans to provide funding and business-building programming to entrepreneurs from groups who are often overlooked by investors through a new fund that will begin this fall.
Accenture (NYSE: ACN) has expanded its metro Washington, D.C. innovation hub with the opening today of a new flagship Cyber Fusion Center, located in Arlington’s Rosslyn business district, designed to help organizations apply new techniques and intelligent tools to defend against data breaches and cyberattacks.
Location: UM BioPark On the Nook Cafe Patio 801 W. Baltimore Street Baltimore Maryland 21201
Date: June 28, 2018, 5:00pm to 6:30pm
Mingle with BioPark tenants, our UM Ventures staff, UMB faculty and leaders in Baltimore’s technology community. On the Nook Patio, weather permitting.
Today the National League of Cities (NLC) announced a new program, City Innovation Ecosystems, dedicated to helping cities thrive in the modern economy. The program marks a major new push by NLC to support regional entrepreneurship, innovation and STEM pathways in a time when too few cities are fully participating in the high-tech, global economy.
We’re hearing more and more about precision medicine and how it can positively impact medicine. But what is preventing it from reaching its full potential, and how can everyone from hospitals to startups help scale it?
The Greater Washington Partnership, an alliance of local CEOs, is launching a formal collaboration program with a swath of regional universities — part of an effort to spur the development of more tech-focused workers.
The DRIVe (Division of Research, Innovation, and Ventures) website looks like it belongs to a VC company rather than a federal agency – smart graphics and succinct descriptions. That’s not an accident. DRIVe is taking a venture approach to solving some intractable health issues.
